Latest news and press releases about Opus Genetics, Inc. (IRD): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation).
Price
| Price | $5.41 |
| Market Cap | $447M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -40.38 |
| EV / EBITDA | -3.16 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1147.63% |
| Return on Invested Capital | -59.29% |
| Return on Assets | -115.75% |
| Gross Margin | 99.87% |
| Operating Margin | -513.47% |
| Net Margin | -1091.82% |
Related companies: ABOS · AGEN · ALEC · CGTX · HURA · INO · MCRB
Explore sector: Healthcare · Biotechnology
More sections of IRD: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks